Consider the source, but ...
Another piece US anti-Ivermectin puzzle may have emerged. On Monday, Pfizer announced that it's launching an accelerated Phase 2/3 trial for a COVID prophylactic pill designed to ward off COVID in those may have come in contact with the disease.
Coincidentally (or not), Pfizer's drug shares at least one mechanism of action as Ivermectin - an anti-parasitic used in humans for decades, which functions as a protease inhibitor against Covid-19, which researchers speculate "could be the biophysical basis behind its antiviral efficiency."
Lo and behold, Pfizer's new drug - which some have jokingly dubbed "Pfizermectin," is described by the pharmaceutical giant as a "potent protease inhibitor."
Raise your hand if you didn't see this coming.
No comments:
Post a Comment